Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amines to Sulfonamides: The Hinsberg Test01:23

Amines to Sulfonamides: The Hinsberg Test

4.3K
The Hinsberg test is a method to identify primary, secondary and tertiary amines, named after its pioneer, Oscar Hinsberg. Here, amines are treated with benzenesulfonyl chloride, also known as the Hinsberg reagent, in the presence of an excess of aqueous base, followed by acidification. Based on the nature of the amines, different changes are observed.
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing sulfonyl...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tiratricol: First Approval.

Drugs·2025
Same author

Recaticimab: First Approval.

Drugs·2025
Same author

Tasurgratinib Succinate: First Approval.

Drugs·2025
Same author

Correction: Fulzerasib: First Approval.

Drugs·2025
Same author

Marstacimab: First Approval.

Drugs·2024
Same author

Correction: Vorasidenib: First Approval.

Drugs·2024
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
11:00

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

279

Sepiapterin: First Approval.

Yvette N Lamb1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|October 15, 2025
PubMed
Summary
This summary is machine-generated.

Sepiapterin (Sephience™) offers a new oral treatment for phenylketonuria (PKU). This therapy enhances phenylalanine metabolism, addressing the enzyme deficiency in PKU patients and receiving regulatory approvals.

More Related Videos

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

10.9K
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.0K

Related Experiment Videos

Last Updated: Jan 6, 2026

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
11:00

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

279
Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

10.9K
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Genetics

Background:

  • Phenylketonuria (PKU) is a genetic disorder characterized by deficient phenylalanine hydroxylase (PAH) activity.
  • This deficiency leads to hyperphenylalaninaemia (HPA), a condition requiring lifelong management.
  • Current treatments aim to reduce phenylalanine levels, but novel therapeutic approaches are needed.

Purpose of the Study:

  • To summarize the development milestones of oral sepiapterin (Sephience™) for PKU treatment.
  • To highlight the regulatory approvals of sepiapterin for hyperphenylalaninaemia in adult and paediatric patients.
  • To provide an overview of sepiapterin's mechanism of action in enhancing PAH activity.

Main Methods:

  • Review of preclinical and clinical development data for sepiapterin.
  • Analysis of regulatory submission and approval processes in the EU and USA.
  • Pharmacological assessment of sepiapterin as a precursor to tetrahydrobiopterin (BH4).

Main Results:

  • Sepiapterin, an oral formulation, demonstrated efficacy in enhancing PAH-mediated phenylalanine metabolism.
  • Received EU approval on June 19, 2025, for HPA in adult and paediatric PKU patients.
  • Received US approval on July 28, 2025, for sepiapterin-responsive HPA in paediatric and adult patients aged ≥ 1 month.

Conclusions:

  • Sepiapterin represents a significant advancement in PKU therapy, offering an oral route for BH4 precursor supplementation.
  • The drug's approval marks a new therapeutic option for managing HPA in a broad patient population.
  • Further research may explore long-term outcomes and broader applications of sepiapterin in metabolic disorders.